Replimune Group (REPL)
(Real Time Quote from BATS)
$10.75 USD
-0.16 (-1.47%)
Updated Sep 23, 2024 11:16 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
REPL 10.75 -0.16(-1.47%)
Will REPL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REPL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REPL
Replimune (REPL) Gains on Positive Data From Melanoma Study
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
Other News for REPL
Strong Phase 2 Results and Regulatory Progress Fuel Buy Rating for Replimune Group
Strong Buy Rating for Replimune Group on Robust Clinical and Regulatory Milestones
Barclays Releases a Buy Rating on Replimune Group (REPL)
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Replimune presents primary analysis data from IGNYTE clinical trial